WO1993024479A1 - Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant - Google Patents
Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant Download PDFInfo
- Publication number
- WO1993024479A1 WO1993024479A1 PCT/FR1993/000505 FR9300505W WO9324479A1 WO 1993024479 A1 WO1993024479 A1 WO 1993024479A1 FR 9300505 W FR9300505 W FR 9300505W WO 9324479 A1 WO9324479 A1 WO 9324479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- formula
- substituents
- alkyl
- general formula
- Prior art date
Links
- 0 CC=C(C(c1c(C)c(N=*)c(C)c(N)c1)=O)O Chemical compound CC=C(C(c1c(C)c(N=*)c(C)c(N)c1)=O)O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the subject of the present invention is new quinolones and more particularly quinolones substituted by a piperidine cycle.
- R is hydrogen or fluorine
- R 1 represents hydrogen, a radical (lower alkyl optionally hydroxylated), an acyl radical derived from an organic carboxylic acid, an alkyl carbonic acid, or an aryl sulfonic acid, or an arylamino carbonyl radical of the form:
- Ar represents an aromatic radical, mono or bicyclic, optionally substituted by one, two or three substituents chosen from lower alkyl, halogens and trifluoromethyl
- T oxygen or sulfur
- X represents hydrogen or fluorine
- Y represents hydrogen or fluorine
- R 3 is chosen from the group consisting of an isopropyl radical, a terbutyl radical, a cyclopropyl radical, a (cyclopropyl) alkyl radical, a phenyl radical or a phenyl radical substituted by one, two or three substituents defined as above
- R 2 represents an oxygen atom linked by a semi-polar bond
- n 0 or 1
- R 1 represents hydrogen, a linear or branched lower alkyl radical, optionally substituted by a hydroxyl or an acyl radical defined as above
- R, R 2 and n are defined as above
- R 3 is a cyclopropyl radical, the amino derivatives of formula IB
- R 1 represents hydrogen, a lower alkyl radical, linear or branched, optionally substituted by a hydroxyl or an acyl radical derived from a carboxylic, carbonic or arylsulfonic acid
- R 3 is a terbutyl radical
- R 3 represents an isopropyl radical
- R 3 represents a phenyl radical, optionally substituted by one, two or three substituents
- R 3 represents a (cyclopropyl) alkyl radical in which the alkyl residue has from 1 to 3 carbon atoms
- the compounds for which ZR 1 is a ureido function are those which are currently preferred.
- R and R 3 have the meanings previously provided
- T oxygen or sulfur
- W is a group ⁇ C-H or ⁇ N
- B is hydrogen or a 5- or 6-membered aromatic structure
- V is hydrogen, a lower alkyl radical, a radical trifluoromethyl or halogen
- the compounds for which ZR 1 is a ureido function are those which are currently preferred.
- the compounds according to the invention can be salified by adding a mineral or organic base.
- the main salts which can be used are those of alkali metals, alkaline earth metals, ammonium, iron, aluminum, alkylamine salts, hydroxyalkylamine salts, phenylalkylamine salts, pyridylalkylamine salts, salts of cyclany lamines, dicyclanylalkoylamine salts ...
- the sodium, lithium, ammonium, N.methylglucamine and tromethanol salts are those presently preferred.
- These compounds can also be salified with a strong mineral or organic acid, when R 1 represents hydrogen, a lower alkyl radical or a lower (hydroxyalkyl) radical.
- R 1 represents hydrogen, a lower alkyl radical or a lower (hydroxyalkyl) radical.
- hydrochlorides, methane sulfonates, lactates or acetates are preferred examples.
- the compounds according to the invention have very marked antibacterial properties, in particular against Gram positive bacteria. They also have the property of being moderately absorbed generally so that their elimination is essentially fecal.
- They can therefore be used effectively as drugs for bacterial infections of the digestive tract, for the treatment of bacterial dysentery, travelers' diarrhea, or intestinal infections. They can also be used topically for the treatment of eye infections or ear canal infections.
- the compounds according to the invention will be used in the form of pharmaceutical compositions in which the active principle of general formula I or one of its salts, is added or mixed with an excipient or an inert non-toxic pharmaceutically acceptable vehicle.
- the most suitable pharmaceutical forms are those intended for administration by the digestive route such as oral solutions or suspensions, granules, capsules, bare or coated tablets, dragees, sachets of powdered flavored or not, sweetened or not, pills or cachets.
- the average dosage depends mainly on the severity of the infection and the sensitivity of the microbial germ to the antibacterial agent.
- the unit dosage ranges from 100 to 600 mg per dose.
- the daily dosage ranges from 200 to 1200 mg divided into 2 to 4 doses.
- the invention also relates to a process for obtaining the compounds of general formula I which consists in reacting a 6-fluoro 7-halo 1-R 3 4-oxo 1, 4-dihydroquinoleine 3-carboxylic acid.
- formula E
- Hal represents an easily exchangeable halogen atom
- R 3 and R have the meanings provided previously
- the invention also relates to a process for converting the amino compound of formula IV into urea or thiourea which consists in subjecting the compound of formula IV to the action of an isocyanate or isothiocyanate of formula
- R, R 3 , T and Ar are defined as above.
- the crystals formed are taken up in 50 cm of edianol and the precipitate is filtered off.
- the precipitate is suspended in 50 cm 3 of water for 30 min then drained, washed with water, with ethanol and dried. 2 g of melting crystals are thus collected (in the Koffler block) above 260 ° C (the yield is 50% of theory).
- the IR spectrum and micro-analysis are in agreement with an anhydrous product.
- the hydrochloride formed by taking up with IN hydrochloric acid (30 cm 3 ) is also above 260 ° C.
- the hydrochloride is in the form of pale yellow crystals, sparingly soluble in water.
- the minimum inhibitory concentrations were measured by a microdilution technique (*) in a liquid medium (Mueller-Hinton broth) in a volume of 100 ⁇ l and for a concentration range from 128 to 0.06 mg / L, prepared from a stock solution of antibiotic grading 512 mg / L.
- the preparation of these mother solutions carried out varied according to the molecules as a function of the solubility criteria.
- the inoculation is done by adding to each well 10 ⁇ l of a physiological water dilution of an 18 H broth in heart / brain broth such that each well contains approximately 106 bacteria / ml.
- the minimum inhibitory concentration is read as the first concentration of non-culture-giving antibiotic, macroscopically visible after 18 H of incubation at 37 °.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93913065A EP0598089A1 (fr) | 1992-05-26 | 1993-05-25 | Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant |
US08/185,918 US5478841A (en) | 1992-05-26 | 1993-05-25 | Fluorinated quinolones, process for their preparation and pharmaceutical preparations containing same |
JP6500257A JPH06509589A (ja) | 1992-05-26 | 1993-05-25 | 新規なフッ素化キノロンと、その製造方法と、それを含む医薬組成物 |
NO940250A NO940250L (no) | 1992-05-26 | 1994-01-25 | Fluorerte kinoloner, fremgangsmaate for fremstilling og farmasoeytiske preparater inneholdende slike |
FI940357A FI940357A (fi) | 1992-05-26 | 1994-01-25 | Uusia fluorattuja kinoloneja, menetelmä niiden valmistamiseksi, ja niitä sisältäviä farmaseuttisia valmisteita |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR92/06404 | 1992-05-26 | ||
FR9206404A FR2692577B1 (fr) | 1992-05-26 | 1992-05-26 | Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993024479A1 true WO1993024479A1 (fr) | 1993-12-09 |
Family
ID=9430170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1993/000505 WO1993024479A1 (fr) | 1992-05-26 | 1993-05-25 | Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant |
Country Status (10)
Country | Link |
---|---|
US (1) | US5478841A (fr) |
EP (1) | EP0598089A1 (fr) |
JP (1) | JPH06509589A (fr) |
CA (1) | CA2114132A1 (fr) |
FI (1) | FI940357A (fr) |
FR (1) | FR2692577B1 (fr) |
HU (1) | HUT67679A (fr) |
NO (1) | NO940250L (fr) |
OA (1) | OA09881A (fr) |
WO (1) | WO1993024479A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO340833B1 (no) * | 2005-03-21 | 2017-06-26 | Janssen Pharmaceutica Nv | 7-aminoalkylidenylheterocykliske kinolon- og naftyridon-forbindelser og farmasøytiske sammensetninger |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0414573A (pt) * | 2003-09-22 | 2006-11-07 | Janssen Pharmaceutica Nv | 7-amino alquilidenil-quinolonas e naftiridonas heterocìclicas |
US20090156577A1 (en) * | 2004-09-09 | 2009-06-18 | Benjamin Davis | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0126355A1 (fr) * | 1983-05-18 | 1984-11-28 | Bayer Ag | Acides amino-7 cyclopropyl-1 difluoro-6,8 dihydro-1,4 oxo-4 quinoléinecarboxyliques-3, procédés pour leur préparation et compositions anti-bactériennes les contenant |
EP0153163A2 (fr) * | 1984-02-17 | 1985-08-28 | Warner-Lambert Company | Acides 1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoléine carboxyliques substitués en 7; acides 1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphtyridine-3-naphtyridine carboxyliques substitués en 7, leurs dérivés et procédé pour leur préparation |
FR2563521A1 (fr) * | 1984-04-26 | 1985-10-31 | Toyama Chemical Co Ltd | Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents antibacteriens les contenant |
EP0241206A2 (fr) * | 1986-03-31 | 1987-10-14 | Sankyo Company Limited | Dérivés d'acide quinoléine-3-carboxylique, leur préparation et utilisation |
EP0287951A2 (fr) * | 1987-04-16 | 1988-10-26 | Otsuka Pharmaceutical Co., Ltd. | Dérivés d'acide 7-Pipérazinyl- ou 7-Morpholino-4- oxo-quinoline-3-carboxylique, leur préparation et leur utilisation comme agents antimicrobiens |
EP0342675A2 (fr) * | 1988-05-19 | 1989-11-23 | Chugai Seiyaku Kabushiki Kaisha | Dérivés de l'acide quinolonecarboxylique |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1092606A (fr) * | 1976-10-05 | 1980-12-30 | Herbert Berger | 1-(n-acylcarbamoyl)-2-cyano-aziridines et procede de preparation |
JPS6089480A (ja) * | 1983-10-21 | 1985-05-20 | Dainippon Pharmaceut Co Ltd | ピリドンカルボン酸誘導体 |
US5097032A (en) * | 1984-07-20 | 1992-03-17 | Warner-Lambert Company | Antibacterial agents - II |
US4657913A (en) * | 1985-04-18 | 1987-04-14 | Warner-Lambert Company | Trifluoro- quinoline -3- carboxylic acids and their use as anti-bacterial agents |
JPH0635457B2 (ja) * | 1985-06-28 | 1994-05-11 | 杏林製薬株式会社 | ピリドンカルボン酸誘導体およびその製造方法 |
JPH089597B2 (ja) * | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
JPS62215572A (ja) * | 1986-03-17 | 1987-09-22 | Kyorin Pharmaceut Co Ltd | キノロンカルボン酸誘導体 |
JPS63198664A (ja) * | 1986-03-31 | 1988-08-17 | Sankyo Co Ltd | キノロンカルボン酸誘導体 |
DE3766299D1 (de) * | 1986-07-04 | 1991-01-03 | Chemie Linz Gmbh | 4-chinolon-3-carbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate. |
US4851418A (en) * | 1987-08-21 | 1989-07-25 | Warner-Lambert Company | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent |
FR2634483B2 (fr) * | 1987-12-29 | 1994-03-04 | Esteve Labor Dr | Derives des acides 7-(1-azetidinyl)-1,4-dihydro-4-oxoquinoleine-3-carboxyliques, leur preparation et leur application en tant que medicaments |
US5173484A (en) * | 1988-02-05 | 1992-12-22 | Bayer Aktiengesellschaft | Quinolone- and naphthyridone carboxylic acid derivatives, process for their production, antibacterial compositions and feed additives containing them |
AU618823B2 (en) * | 1988-07-20 | 1992-01-09 | Sankyo Company Limited | 4-oxoquinoline-3-carboxylic acid derivatives, their preparation and their use |
US5328908A (en) * | 1988-10-24 | 1994-07-12 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolone thioureas |
DE3918544A1 (de) * | 1989-06-07 | 1990-12-13 | Bayer Ag | Verfahren zur herstellung von 7-(3-amino- sowie 3-amino-methyl-1-pyrrolidinyl)-3-chinolon- carbonsaeuren sowie -naphthyridoncarbonsaeuren |
US5047538A (en) * | 1990-04-12 | 1991-09-10 | Warner-Lambert Company | Quinolinecarboxylic acid antibacterial agents |
US5116834A (en) * | 1990-04-12 | 1992-05-26 | Warner-Lambert Company | Quinolinecarboxylic acid antibacterial agents |
US5342846A (en) * | 1990-12-05 | 1994-08-30 | Synphar Laboratories, Inc. | 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents |
FR2673426B1 (fr) * | 1991-03-01 | 1993-07-16 | Bouchara Sa | Nouvelles quinolones, leur procede de preparation et les compositions en refermant. |
US5250532A (en) * | 1991-04-11 | 1993-10-05 | Dowelanco | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides |
US5221676A (en) * | 1992-02-06 | 1993-06-22 | Warner-Lambert Company | 7-substituted quinolones and naphthyridones as antibacterial agents |
-
1992
- 1992-05-26 FR FR9206404A patent/FR2692577B1/fr not_active Expired - Lifetime
-
1993
- 1993-05-25 HU HU9400211A patent/HUT67679A/hu unknown
- 1993-05-25 CA CA002114132A patent/CA2114132A1/fr not_active Abandoned
- 1993-05-25 JP JP6500257A patent/JPH06509589A/ja active Pending
- 1993-05-25 EP EP93913065A patent/EP0598089A1/fr not_active Withdrawn
- 1993-05-25 US US08/185,918 patent/US5478841A/en not_active Expired - Fee Related
- 1993-05-25 WO PCT/FR1993/000505 patent/WO1993024479A1/fr not_active Application Discontinuation
-
1994
- 1994-01-24 OA OA60462A patent/OA09881A/fr unknown
- 1994-01-25 NO NO940250A patent/NO940250L/no unknown
- 1994-01-25 FI FI940357A patent/FI940357A/fi not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0126355A1 (fr) * | 1983-05-18 | 1984-11-28 | Bayer Ag | Acides amino-7 cyclopropyl-1 difluoro-6,8 dihydro-1,4 oxo-4 quinoléinecarboxyliques-3, procédés pour leur préparation et compositions anti-bactériennes les contenant |
EP0153163A2 (fr) * | 1984-02-17 | 1985-08-28 | Warner-Lambert Company | Acides 1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoléine carboxyliques substitués en 7; acides 1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphtyridine-3-naphtyridine carboxyliques substitués en 7, leurs dérivés et procédé pour leur préparation |
FR2563521A1 (fr) * | 1984-04-26 | 1985-10-31 | Toyama Chemical Co Ltd | Derives de la 1,4-dihydro-4-oxonaphtyridine et leurs sels, procede pour leur production et agents antibacteriens les contenant |
EP0241206A2 (fr) * | 1986-03-31 | 1987-10-14 | Sankyo Company Limited | Dérivés d'acide quinoléine-3-carboxylique, leur préparation et utilisation |
EP0287951A2 (fr) * | 1987-04-16 | 1988-10-26 | Otsuka Pharmaceutical Co., Ltd. | Dérivés d'acide 7-Pipérazinyl- ou 7-Morpholino-4- oxo-quinoline-3-carboxylique, leur préparation et leur utilisation comme agents antimicrobiens |
EP0342675A2 (fr) * | 1988-05-19 | 1989-11-23 | Chugai Seiyaku Kabushiki Kaisha | Dérivés de l'acide quinolonecarboxylique |
Non-Patent Citations (5)
Title |
---|
CHEMICAL ABSTRACTS, vol. 106, no. 23, 8 Juin 1987, Columbus, Ohio, US; abstract no. 196291v, NARITA HIROKAZU ET AL. * |
J. MED. CHEM. vol. 35, no. 2, 24 Janvier 1992, pages 361 - 367 J.P. SANCHEZ ET AL. * |
J. MED. CHEM. vol. 35, no. 8, 17 Avril 1992, pages 1392 - 1398 C.S. COOPER ET AL. * |
PATENT ABSTRACTS OF JAPAN vol. 15, no. 193 (C-832)17 Mai 1991 * |
PATENT ABSTRACTS OF JAPAN vol. 9, no. 228 (C-303)(1951) 13 Septembre 1985 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO340833B1 (no) * | 2005-03-21 | 2017-06-26 | Janssen Pharmaceutica Nv | 7-aminoalkylidenylheterocykliske kinolon- og naftyridon-forbindelser og farmasøytiske sammensetninger |
Also Published As
Publication number | Publication date |
---|---|
NO940250D0 (no) | 1994-01-25 |
JPH06509589A (ja) | 1994-10-27 |
FR2692577A1 (fr) | 1993-12-24 |
OA09881A (fr) | 1994-09-15 |
CA2114132A1 (fr) | 1993-12-09 |
US5478841A (en) | 1995-12-26 |
HUT67679A (en) | 1995-04-28 |
EP0598089A1 (fr) | 1994-05-25 |
FI940357A0 (fi) | 1994-01-25 |
HU9400211D0 (en) | 1994-05-30 |
FI940357A (fi) | 1994-03-28 |
FR2692577B1 (fr) | 1996-02-02 |
NO940250L (no) | 1994-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0208210B1 (fr) | Dérivés de l'acide pyridonecarboxylique et procédé pour leur préparation | |
FR2555584A1 (fr) | Derives de l'acide fluoro-6-dihydro-1,4-oxo-4-piperazinyl substitue-7-quinoline-carboxylique-3 et procede pour leur preparation et compositions pharmaceutiques a action anti-bacteriennes a base desdits derives | |
EP0385850A2 (fr) | Nouveaux dérivés de benzimidazoles et azabenzimidazoles, leurs procédés de préparation, intermédiaires de synthèse, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et les ulcères duodénaux | |
FR2645152A1 (fr) | 3h-pteridinones-4, procedes de preparation et medicaments les contenant | |
EP0611766A1 (fr) | Dérivés de 2-amido-thiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament | |
EP0067772B1 (fr) | Nouveaux dérivés du N-dihydrothiazolyl 3-quinoléine carboxamide, leurs sels, leur procédé de préparation, leur application à titre de médicaments et les compositions les renfermant | |
FR2501204A1 (fr) | Derives d'un acide quinoleine-carboxylique, procede pour les preparer et medicament en contenant | |
EP0134165B1 (fr) | Dérivés 7-(pyrrol-1-yl) des acides 1-éthyl-1,4-dihydro-4-oxoquinoléine-3-carboxyliques et 1-éthyl-1,4-dihydro-4-oxo-(1,8-naphtyridine)-3-carboxyliques substitués, leur préparation et leur application en tant que médicaments | |
EP0115049B1 (fr) | Dérivés de l'acide 1-éthyl-6,8-difluoro-1,4-dihydro-7-(1-imidazolyl)-4-oxoquinoléinecarboxylique, procédé pour leur préparation et des compositions antibactériennes | |
FR2537140A1 (fr) | Nouveaux derives de la 4-hydroxy-3-quinoleine carboxamide, leur sels, procede de preparation, application a titre de medicaments, et compositions les renfermant | |
CH633556A5 (fr) | Amides therapeutiquement actifs et procedes pour les produire. | |
JPS59101467A (ja) | 6,7−ジヒドロ−8−(イミダゾ−ル−1−イル)−5−メチル−1−オキソ−1H,5H−ベンゾ〔ij〕キノリジン−2−カルボン酸およびその誘導体 | |
WO1993024479A1 (fr) | Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant | |
FR2491064A1 (fr) | Quinolones, leurs procedes de preparation et composition therapeutique les contenant | |
US5420140A (en) | Difluorinated quinolones useful for treating bacterial infections | |
EP0136198B1 (fr) | Dérivés de triazolo pyrimidine, leur procédé de préparation et leur application thérapeutique en tant que toni-cardiaques | |
EP0196943B1 (fr) | Nouveaux dérivés 8-thiotétrahydroquinoléines et leurs sels | |
US4791118A (en) | Quinolonecarboxylic acid derivatives and their preparation | |
WO1992015574A1 (fr) | Nouvelles quinolones, leur procede de preparation et les compositions pharmaceutiques en renfermant | |
EP0168309B1 (fr) | Nouveaux dérivés de l'isoxazoloquinoléinone, procédé et intermédiaires de préparation, application à titre de médicaments, et compositions les renfermant | |
FR2674854A1 (fr) | Nouvelles quinolones leur procede de preparation et les compositions pharmaceutiques en refermant. | |
EP0530355A1 (fr) | Nouvelles quinolones fluorees, leur procede de preparation, et les compositions pharmaceutiques en renfermant | |
EP0221541A2 (fr) | Dérivés de l'acide quinoléinonecarboxylique et leur préparation | |
FR2694751A1 (fr) | Nouveaux dérivés sulfonamides, leurs procédés de préparation et les compositions en renfermant. | |
US4567269A (en) | Intermediates for the preparation of 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993913065 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2114132 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 940357 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08185918 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1993913065 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993913065 Country of ref document: EP |